UK NICE rejects the use of Kanuma (sebelipase alfa) to treat lysosomal acid lipase deficiency- Alexion
The UK's National Institute for Health and Care Excellence has published its a final evaluation which rejects the use of Kanuma (sebelipase alfa), from Alexion, to treat infants, children and adults with the rare inherited genetic disorder lysosomal acid lipase deficiency (LAL-D).
In clinical trials with Kanuma, five out of nine infants survived beyond three years of age, achieving normal developmental milestones, the firm noted. But the high cost of the drug - nearly £500,000 per patient - could not be justified by its long-term treatment benefits.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins